Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Elizabeth Clutterbuck and Sue Charlton.
Elizabeth Clutterbuck
Connection Strength
0.292
Sue Charlton
  1. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 09 04; 398(10303):856-869.
    View in: PubMed
    Score: 0.060
  2. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 04 10; 397(10282):1351-1362.
    View in: PubMed
    Score: 0.059
  3. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021 04 29; 184(9):2348-2361.e6.
    View in: PubMed
    Score: 0.058
  4. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021 04 15; 184(8):2201-2211.e7.
    View in: PubMed
    Score: 0.058
  5. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 12 19; 396(10267):1979-1993.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.